Introduction {#s1}
============

Sepsis is one of the leading causes for mortality and persistent impairment world-wide ([@B1], [@B2]) and new therapeutic approaches are highly needed. A hallmark of sepsis is the systemic inflammatory response. It is characterized by increased release of damage-associated molecular patterns (DAMPs) and unbalanced activation of the innate immune system ([@B3]). Excessive secretion of pro-inflammatory cytokines is considered as one major driver of early mortality in sepsis by mediating capillary leakage and hemodynamic instability ([@B3]). Systemic inflammation occurs also in non-infectious conditions such as post-cardiac arrest syndrome, burn or trauma. Cytokine adsorption has been proposed as a new approach to target systemic inflammation ([@B3]). The CytoSorb hemoadsorption device (CytoSorbents Europe, Berlin, Germany) contains porous polymer beads that adsorb molecules within the 5--55 kDa range including many cytokines and DAMPs and eliminates them from the circulation ([@B4]--[@B6]). CytoSorb has already entered clinical application ([@B7]) and randomized clinical trials on sepsis, pancreatitis (clinicaltrials.gov NCT03082469) or heart surgery (clinicaltrials.gov NCT02265419) are ongoing.

Extracorporeal membrane oxygenation (ECM) is more and more available and used to bridge respiratory or circulatory failure from different causes ([@B8], [@B9]). However, there is only little experience in the application of cytokine adsorption in patients while on ECMO ([@B10]--[@B13]). Thus, we aimed to evaluate the feasibility of cytokine adsorption in critically ill patients undergoing ECMO therapy.

Methods {#s2}
=======

Patient Selection
-----------------

We present a series of six cases from a single-center registry of patients treated with venovenous (vv) or venoarterial (va) ECMO therapy at the 30-bed medical intensive care unit of the Department of Medicine III (Interdisciplinary Intensive Care), Medical Center, University of Freiburg and Heart Center Freiburg University between July 2015 and April 2017. Data were blinded to patient identity. The study protocol was approved by the local Independent Ethics Committee (Freiburg 151/14) and the study complies with the Declaration of Helsinki.

Technical Implementation of Cytokine Adsorption During ECMO Therapy
-------------------------------------------------------------------

Cannulation for veno-arterial or veno-venous ECMO was performed in Seldinger\'s technique bi-femoral or by usage of a double-lumen venous cannula as previously described ([@B14], [@B15]). During ECMO therapy, a CytoSorb hemoadsorption device (CytoSorbents Europe, Berlin, Germany) was integrated into the ECMO circuit (SCPC, Sorin Munich Germany). The CytoSorb adsorber was connected at the arterial oxygenator (EOS ECMO, LivaNova Mirandola, Italy) outlet via an 3-way stop-cock (tube length 50 cm, inner diameter 4.8 mm) and was returned into the venous line before the centrifugal pump (Revolution, LivaNova Mirandola, Italy) ([Figure 1](#F1){ref-type="fig"}) as reported previously ([@B16], [@B17]). Blood flow rates through the CytoSorb device were between 150 and 300 ml/min as calculated from blood flow rates before and after return into the venous line ([Figure 1](#F1){ref-type="fig"}). Integration of the adsorber required no or a few seconds halt of the system.

![Technical implementation of the cytokine adsorber into the ECMO circuit. The CytoSorb adsorber was connected in parallel, placed at the arterial oxygenator outlet via an 3-way stop-cock and was returned into the venous line before the centrifugal pump. Blood flow was measured before and after the 3-way stop-cock in the venous line.](fcvm-06-00071-g0001){#F1}

Data Acquisition
----------------

Horowitz index and SOFA score were calculated using onset of ECMO therapy as index event. Norepinephrine, epinephrine, dobutamine and vasopressin were used as vasopressor or inotropic agents, respectively. To allow easier comparison, we derived dose equivalents by dividing the applied dose by the patient\'s individual maximum dose for each agent. The sum of dose equivalents for all agents used in one case is termed "adjusted dose equivalent" in this manuscript (range 0--4). Vasopressor or inotrope use, fluid balance and plasma lactate levels are given as mean of all available values within 24 h before (pre) or after (post) onset of cytokine adsorption. Laboratory findings are given for the latest measurement before (pre) or within 24 h after (post) onset of cytokine adsorption.

Statistical Analysis
--------------------

Data are presented as mean ± SEM and were compared using paired *t*-test with *P* \< 0.05 considered to be significant. All statistical analyses were performed using GraphPad Prism 5.04.

Results {#s3}
=======

We identified six patients in our registry that received cytokine adsorption while undergoing ECMO therapy for septic shock (*n* = 4) or after cardiac arrest (*n* = 2) ([Figure 2](#F2){ref-type="fig"}). Patient characteristics, laboratory findings and treatment and outcome parameters are outlined in [Table 1](#T1){ref-type="table"}. Mean SOFA score at the time of ECMO onset was 16.3 ± 1.2.

![Outcome parameters in patients undergoing cytokine adsorption during ECMO therapy. Mean vasopressor or inotropes use **(A)**, mean fluid balance per hour **(B)** and mean arterial lactate concentration as a surrogate parameter of shock **(C)** were determined within 24 h before (pre) and after (post) onset of cytokine adsorption. The time courses of vasopressor or inotropes use **(D)**, fluid balance **(E)** and arterial lactate concentration **(F)** are depicted from 6 h before to 24 h after onset of cytokine adsorption (dashed line). Levels of procalcitonin in septic patients **(G)** or interleukin 6 in patients after cardiac arrest **(H)** were determined during 4 days after onset of cytokine adsorption. Blue circle, case 1; blue square, case 2; blue diamond, case 3; blue triangle, case 4; red circle, case 5; red square, case 6.](fcvm-06-00071-g0002){#F2}

###### 

Patient characteristics, laboratory findings and outcome.

                                                     **Case 1**     **Case 2**     **Case 3**     **Case 4**      **Case 5**        **Case 6**        **Overall**
  ----------------------------- -------------------- -------------- -------------- -------------- --------------- ----------------- ----------------- -----------------
  **Sex category**              Female/male          Female         Female         Male           Male            Male              Male              2/4
  **Age**                       Years                44             31             34             68              68                18                43.8 ± 7.6
  **Indication for ECMO**                            ARDS, septic   ARDS, septic   ARDS, septic   Septic shock,   Cardiac arrest,   Cardiac arrest,   
  ARDS                                               shock          shock          shock          cardiac shock   cardiac shock     cardiac shock     3 (50.0 %)
  Septic shock                                                                                                                                        4 (66.7 %)
  Cardiac arrest                                                                                                                                      2 (33.3 %)
  Cardiac shock                                                                                                                                       3 (50.0 %)
  **Laboratory findings**                                                                                                                             
  Hemoglobin                    g/dl                 8.5            8.5            5.9            9.0             8.1               13,4              8.9 ± 0.9
  Leukocytes                    103/μl               33.0           24.0           46.5           23.9            16.2              13.0              26.1 ± 4.5
  Platelets                     103/μl               106.0          29.0           69.0           114.0           148.0             230               115.0 ± 25.8
  Kreatinin                     mg/dl                3.9            2.0            4.3            3.5             1.3               1.8               2.8 ± 0.5
  C-reactive protein            mg/l                 284            190            207            125             3                 3                 135.3 ± 42.6
  Creatine kinase               U/l                  1439           1895           463            892             1556              12889             3189.0 ± 1781.1
  Myoglobin                     mg/ml                7393           8486           340            3672            2689              37380             9993.3 ± 5125.0
  **Horowitz index**                                 89.1           70.1           60.0           102.9           126.0             158.0             101.0 ± 13.6
  **SOFA score**                                     18             17             21             17              13                12                16.3 ± 1.2
  **ECMO category**             ven.-ven./ven-art.   ven.-ven.      ven.-ven.      ven.-ven.      ven.-art        ven.-art          ven.-art          3/3
  **Cytokine adsorption**                                                                                                                             
  Initiation after ECMO onset   Hours                3.9            0.6            7.5            0.0             0.0               3.0               2.5 ± 1.1
  Treatment duration            Hours                38.4           12.0           13.5           15.0            67.7              28.5              29.2 ± 8.0
  Number of adsorbers                                2              1              1              1               2                 2                 1.5 ± 0.2
  **Mortality**                                                                                                                                       
  ICU mortality                                                     Yes            Yes            Yes             Yes               Yes               5/6 (83.3 %)
  30-days mortality                                                 Yes            Yes            Yes             Yes               Yes               5/6 (83.3 %)
  Time to mortality             Days                                1.0            0.6            0.6             20.5              3.3               5.2 ± 3.4
  **Adverse events**                                                                                                                                  
  Bleeding                                                                                        Yes                                                 1/6 (16.7 %)
  Secondary infection                                                                                             Yes                                 1/6 (16.7 %)

*ARDS, acute respiratory distress syndrome; ECMO, extracorporeal membrane oxygenation; SOFA, sepsis-related organ failure*.

Cytokine adsorption was initiated early after ECMO onset. CytoSorb®adsorbers were integrated into the extracorporeal circulation without technical difficulties. In three patients, the adsorber was renewed during ECMO therapy. Mean duration of cytokine adsorption in the collective was 29.2 ± 8.0 h ([Table 1](#T1){ref-type="table"}).

To determine the therapeutic impact of cytokine removal we measured surrogate parameters of clinical outcome. Cytokine adsorption did not influence the use of vasopressors or inotropes, fluid balance and arterial blood lactate concentrations ([Figures 2A--F](#F2){ref-type="fig"}) in the total collective. ICU mortality was 83.3% with a mean time to mortality of 10.7 days ([Table 1](#T1){ref-type="table"}). Serum interleukin 6 levels during the course of treatment were available in two cases. Cytokine adsorption lead to a rapid decrease of interleukin 6 by \~85% within the first 24 h of treatment ([Figures 2G,H](#F2){ref-type="fig"}).

We evaluated potential differences in the effectiveness of cytokine removal for different pathologies. In two patients treated after cardiac arrest we found a decrease in lactate concentration or decelerated increase of cumulative fluid balance, respectively, from approximately 6 h after onset of cytokine removal ([Figure 2](#F2){ref-type="fig"}).

We aimed to assess the safety of cytokine adsorption during ECMO therapy. We did not experience air embolism or hemodynamic or respiratory failure during the technical implementation of the adsorber into the ECMO circuit. Platelet count significantly decreased to 61.2 ± 12.5 × 103/μl during the first 24 h of cytokine adsorption ([Figure 3A](#F3){ref-type="fig"}). We found no evidence of altered plasmatic coagulation ([Figure 3B](#F3){ref-type="fig"}). In one case, relevant bleeding occurred during therapy. Of note, this patient had initially presented with marked coagulopathy due to sepsis. In one case, severe infection occurred within days after cytokine adsorption finally leading to fatal septic shock.

![Indicators for adverse effects of cytokine adsorption during ECMO therapy. Platelet count **(A)** and international normalized ratio (INR, **B**) were determined before (pre) and after (post) onset of cytokine adsorption. Blue, septic shock; red, cardiac arrest. Blue circle, case 1; blue square, case 2; blue diamond, case 3; blue triangle, case 4; red circle, case 5; red square, case 6.](fcvm-06-00071-g0003){#F3}

Discussion {#s4}
==========

We report here data from six cases in our single center registry on critically ill patients that received cytokine adsorption while undergoing ECMO therapy. We describe a procedure to integrate a cytokine adsorber device into the ECMO circuit. Our data suggest that incorporation of cytokine adsorption during continued ECMO support was feasible.

Cytokine adsorption has entered clinical application in many intensive care centers and clinicians have provided many patients with this novel treatment option based on an individual, informed or life-threatening urgent treatment decision. Due to the lack of published data from randomized controlled trials, neither indication nor application, duration, or co-treatment have been described in national or international guidelines.

A number of cases have been reported in which cytokine adsorption has been applied for septic shock ([@B18]--[@B20]). We have previously observed astonishingly beneficial effects in a patient with severe hemophagocytic lymphohistiocytosis with rapid clinical recovery during cytokine removal ([@B21]). The results obtained from a case series of 26 patients and a recently published prospective trial on 20 patients with septic shock indicate that cytokine adsorption promotes hemodynamic stabilization and lactate clearance ([@B22], [@B23]). We did not observe a significant improval of outcome parameters in septic patients who underwent cytokine adsorption. However, the number of cases included in our study is too low to properly address this point.

Cytokine adsorption has been used in other states of non-infectious systemic inflammation, including liver transplantation ([@B24]), cardiopulmonary bypass surgery ([@B25], [@B26]) or cardiogenic shock ([@B17]). We hypothesized that cytokine adsorption might be an effective measure in patients presenting with post-cardiac arrest syndrome. Post-cardiac arrest syndrome is characterized by a severe systemic inflammatory response, which is associated with impaired hemodynamics ([@B27]) and increased mortality ([@B28]). Elevated markers of systemic inflammation such as interleukin 6 drive vascular permeability and leakage ([@B29]), a key characteristic of patients with systemic inflammation ([@B30]), and are predictors of high mortality and poor neurological outcome ([@B31], [@B32]).

Capillary leakage leads to impaired tissue perfusion and hypoxia which is reflected by increased serum lactate. In patients undergoing va-ECMO therapy after cardiac arrest or during cardiac shock increased serum lactate is associated with adverse outcome and serial lactate measurements allow to predict mortality ([@B33], [@B34]). In addition, capillary leakage and increased serum lactate frequently trigger a positive fluid balance, which is *per se* associated with poor outcome ([@B15]). It has been suggested that cytokine adsorption restores vascular barrier function ([@B20]) and thus might improve fluid balance and outcome of patients with shock. In two patients who underwent va-ECMO therapy after cardiac arrest, fluid balance and arterial lactate levels markedly lowered from approximately 6 h after onset of cytokine adsorption. This might suggest an additional beneficial effect of cytokine adsorption to va-ECMO therapy during post-cardiac arrest care.

Usually, cytokine adsorbers are integrated into an extracorporeal hemofiltration circuit ([@B7]). Additional vascular access might be occupied be ECMO cannulas and lead to access-related complications, thus it has been attempted to incorporate cytokine adsorbers into running systems. In patients undergoing cardiac surgery, cytokine adsorbers have been connected to the cardiopulmonary bypass ([@B26], [@B35]). Incorporation of the adsorber device into the ECMO circuit as described here is fast and safe and can be easily performed in an intensive care unit setting. This confirms the experiences made at other centers ([@B12], [@B13], [@B17]). Possible complications such as air embolism that may arise from negative pressure in the pre-pump circuit or abnormalities in blood flow were not observed. In a previous study, a similar setup as described here, incorporating chronic renal replacement therapy into an ECMO circuit, has successfully been tested for safety ([@B16]). This approach allows earliest possible initiation of cytokine adsorption in critically ill patients requiring ECMO support. In particular after cardiac arrest this might be a decisive advantage to prevent early onset post-resuscitation syndrome. In addition, it has been suggested that the ECMO itself triggers an inflammatory response due to the exposure of a patient\'s blood to the non-endothelialised surface of the ECMO circuit ([@B36]) and this might be targetable by cytokine adsorber.

Conclusions {#s5}
===========

Taken together, these data suggest that incorporation of cytokine adsorption into the management of critically ill patients requiring continued ECMO support is feasible and easy to handle. Whether cytokine removal improves clinical outcome in ECMO-treated patients after cardiac arrest should be investigated in a prospective clinical trial.
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